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Summary Cardiac troponin (cTn) assays have quickly gained in analytical sensitivity to
become what are termed ‘high-sensitivity cardiac troponin’ (hs-cTn) assays, bringing a ﬂurry of
dense yet incomplete literature data. The net result is that cTn assays are not yet standardized
and there are still no consensus-built data on how to use and interpret cTn assay results. To
address these issues, the authors take cues and clues from multiple disciplines to bring responses
to frequently asked questions. In brief, the effective use of hs-cTn hinges on knowing: speciﬁc
assay characteristics, particularly precision at the 99th percentile of a reference population;
factors of variation at the 99th percentile value; and the high-individuality of hs-cTn assays, for
which the notion of individual kinetics is more informative than straight reference to ‘normal’
values. The signiﬁcance of patterns of change between two assay measurements has not yet
been documented for every hs-cTn assay. Clinicians need to work hand-in-hand with medical
biologists to better understand how to use hs-cTn assays in routine practice.
© 2014 Elsevier Masson SAS. All rights reserved.
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Résumé L’évolution rapide des méthodes de dosage des troponines cardiaques (cTn) vers
une meilleure sensibilité analytique (cTn de haute sensibilité, ou cTn HS) s’accompagne de
nombreuses données de la littérature mais encore incomplètes. En l’absence de standardisation
des cTn et de données consensuelles sur l’utilisation et l’interprétation des résultats, les auteurs
de cette revue proposent, à partir d’une revue de la littérature, et de fac¸on multidisciplinaire,
des éléments de réponses aux questions fréquemment posées. En conclusion, le bon usage
des cTn HS repose sur la connaissance : des caractéristiques propres de la méthode utilisée,
en particulier de la précision obtenue au 99e percentile d’une population de référence ; des
facteurs de variation de la valeur du 99e percentile ; de la forte individualité des dosages de
cTn HS, pour lesquels la notion de cinétique individuelle est plus informative que la simple
référence à des valeurs usuelles. La signiﬁcativité des variations entre deux dosages, n’est pas
encore documentée pour toutes les méthodes HS. La collaboration entre cliniciens et biologistes
est nécessaire à une meilleure utilisation des troponines au quotidien.
© 2014 Elsevier Masson SAS. Tous droits réservés.
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International guidelines on myocardial infarction (MI) diag-
nosis recommend running a cardiac troponin (cTn) assay in
suspected MI patients unless they present ST-segment ele-
vation (suspected lone-event non-ST-segment elevation MI
[NSTEMI]). The need to observe an increase in troponin over
the 99th percentile of a reference population together with
the signiﬁcant assay-to-assay variation make it necessary to
use what are dubbed sensitive or hypersensitive cTn assays.
cTn assays are rapidly gaining in analytical sensitivity. Pub-
lished data on this latest generation of more sensitive assays
are dense, but are still incomplete. Furthermore, cTn assays
are not yet standardized and there are still no consensus-
built data on how to use and interpret high-sensitivity cTn
(hs-cTn) assay results.
Given this context, three French academic societies
— the Société franc¸aise de médecine d’urgence (SFMU) for
emergency medicine, the Société franc¸aise de cardiologie
(SFC) for cardiology and the Société franc¸aise de biologie
clinique (SFBC) for clinical biology— have joined forces to
co-propose an integrated French-language document that,
through a review of the literature, tackles the issue of how
to use troponin assays properly. The document adopts a
o
t
b
rQuestion and Answer’ format to connect with grass-roots
ractitioners, and is written to provide clinicians and biol-
gists with the most routine-relevant conclusions possible,
ncluding a series of boxes headed ‘In practice/takeaways’,
hich recap the key messages.
erms and deﬁnitions
hat does assay sensitivity mean?
n assay that qualiﬁes as sensitive or hypersensitive (quali-
ers arbitrarily grouped under the term ‘high-sensitivity’ in
his paper) is an assay that demonstrates greater analytical
ensitivity and precision than the conventional method it is
uilt on. The word ‘sensitive’ refers to the assay, not to the
iomarker itself.
From an analytical standpoint, analytical sensitivity is the
mallest measurable analyte concentration above the limit
f detection. Here, sensitivity is determined by the slope of
he calibration curve. Higher sensitivity increases the possi-
ility of getting low variations between two assays, as their
espective signals will be signiﬁcantly different (Fig. 1).
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Figure 1. Graphical comparison of the sensitivity of two assays.
Assay B sensitivity is higher than assay A sensitivity; it is easier to
detect a small difference of concentration between two measures
(black arrow) with assay B because the difference between observed
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cTnI [cardiac troponin I] upgraded to ARCHITECT hs-cTnIignals is higher for assay B (blue arrow) than for assay A (turquoise
lue arrow).
n other words, a method’s sensitivity is also its ability to
recisely and reliably differentiate between two different
oncentrations.
In practice/takeaways
• The word ‘sensitive’ refers to the assay, not to the
biomarker itself.
• Analytical sensitivity is the smallest difference in
concentration measurable by the assay.
hat does analytical precision mean?
he analytical precision of an assay is an evaluation of the
egree of dispersion in serial test results on a single sample;
t is expressed as the analytical coefﬁcient of variation (CV)
f the assay, where CV =mean/standard deviation× 100,
iven as a percentage (%). Analytical precision splits into
repeatability strand (intraseries precision) and a repro-
ucibility strand (interseries precision).
A measurement method’s lower-range limits are deﬁned
y: the Limit of Blank (LoB; the concentration below which
5% of results are expected to be found when replicates
n > 60] of a sample containing no analyte [i.e. a biomarker-
ree sample] are measured); the Limit of Detection (LoD; the
owest detectable analyte concentration likely to be reliably
istinguished from the LoB; it is determined based on the
oB and the standard deviation of replicates of a sample
ontaining a low, but non-zero, biomarker concentration);
he Limit of Quantitation (LoQ; the smallest value obtained
t a predeﬁned CV). In the speciﬁc subﬁeld of cTn, and for
onventional assay methods, 10% CV is the analytical limit
dopted for MI diagnosis [1].
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Precision, LoD and LoQ vary from cTn assay to cTn assay,
o they need to be veriﬁed by the laboratories and, if
ppropriate, communicated to the clinicians, to optimize
he results interpretation process. Within the laboratory
ompetency accreditation framework (standard ISO 15189),
he analytical characteristics of hs-cTn assays are to be
eriﬁed as stipulated in document SH-GTA 04 (see ‘What pre-
autions does the laboratory need to take when transitioning
o a hs-cTn assay?’).
In practice/takeaways
• The analytical precision of an assay is given by the
CV at a given analyte concentration.
• Analytical characteristics (sensitivity, precision, LoD,
LoQ) are assay speciﬁc.
hat is an hs-cTn assay and are all hs-cTn
ssays essentially similar?
n hs-cTn assay possesses better sensitivity and better ana-
ytical precision than the ‘conventional’ assay it is built on.
igh-sensitivity assays offer 4-fold to 10-fold greater ana-
ytical sensitivity than conventional methods.
Apple and Collinson short-listed two basic criteria for
eﬁning whether a cTn assay is ‘highly sensitive’: precision
f a reference population; and proportion of measurable
oncentrations in healthy individuals above the assay’s LoD
2]. For an assay to qualify as’ high-sensitivity’, it has to
emonstrate≤ 10% total imprecision at the 99th percentile
alue and be able to quantitate at least 50% of healthy indi-
iduals [2].
cTn assays —whether high-sensitivity or conventional—
re still not standardized at this time. Standardization
fforts are hampered by a combination of factors, chieﬂy
he heterogeneity of the circulating cTn forms that the
ssays can recognize, post-translational modiﬁcations to cTn
soforms and immunoassay response modiﬁcations tied to
nterferences and autoantibodies.
Compounding the issue, results do not directly corre-
ate from technique to technique. In theory, the assays are
quimolar, which means they should identically recognize all
irculating forms. In practice, however, the distribution of
irculating cTn forms in a given patient at a given time can
ary, thus producing different responses in different assays.
onsequently, the results given by different assays are not
irectly transposable from test to test.
The net result is that each assay method has its own char-
cteristics and its own cut-off thresholds (Table 1) [3—5].
onsequently, it is vital that a patient’s cTn concentra-
ions are monitored with the same assay. The high-sensitivity
ssays add to a long list of conventional cTn assays. In most
ases, the high-sensitivity method has replaced the conven-
ional assay (e.g. fourth-generation cTnT [cardiac troponin
] upgraded to hs-cTnT at Roche Diagnostics, ARCHITECTt Abbott, etc.). The analytical modiﬁcations integrated in
igh-sensitivity assays are patent protected and are rarely
ublished.
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Table 1 Market offer for automated quantitative troponin assays in France: 31 August 2013.
Manufacturer Analyser LoB LoD LoQa 99th
percentile
values
99th
percentile
CV
Conventional assays
Abbott AxSYM 0.020g/L NA 0.160g/L 0.040g/L 14%
ARCHITECT < 0.010g/L NA 0.032g/L 0.028g/L 14%
i-STAT 0.020g/L NA 0.100g/L 0.080g/L 17%
Alere Triage Cardio3b 0.002g/L 0.010g/L 0.040g/L 0.020g/L 17%
Beckman Access Accu 0.010g/L NA 0.060g/L 0.040g/L 14%
bioMérieux VIDAS Ultra < 0.010g/L < 0.010g/L 0.110g/L 0.010g/L 28%
Radiometer AQT90 TnTb NA 0.008g/L 0.026g/L 0.017g/L 15%
AQT90 TnIb NA 0.010g/L 0.039g/L 0.023g/L 17%
Response Biomedical RAMP 0.030g/L 0.030g/L 0.210g/L 0.100g/L 20%
Siemens Dimension RxL 0.040g/L NA 0.140g/L 0.070g/L 15—22%
IMMULITE 0.100g/L NA 0.220g/L 0.190g/L 11%
Tosoh AIA II 2G 0.060g/L NA NA 0.060g/L 9%
High-sensitivity assays
Abbott ARCHITECTc 1.3 ng/L 1.9 ng/L 4.7 ng/L 26.2 ng/L 4.0%
Beckman Coulter Accessc 2 ng/L 3 ng/L 8.6 ng/L 8.6 ng/L 10%
Mitsubishi PATHFASTb 2 ng/L 8 ng/L 14 ng/L 29 ng/L 5.0%
Ortho Clinical
Diagnostics
VITROS ECic 7 ng/L 12 ng/L 34 ng/L 34 ng/L 10%
Roche Diagnostics Elecsys/Modular
E/cobas e
3 ng/L 5 ng/L 13 ng/L 14 ng/L 9%
Siemens Healthcare ADVIA Centaur 6 ng/L NA 30 ng/L 40 ng/L 9%
Vista 15 ng/L NA 45 ng/L 45 ng/L 10%
Vista HSc 0.5 ng/L 3 ng/L 9 ng/L 5%
Stratus CSb 30 ng/L NA 60 ng/L 70 ng/L 10%
Dimension EXL 10 ng/L 17 ng/L 50 ng/L 56 ng/L 10%
Tosoh AIA 3G 8 ng/L 20 ng/L 35 ng/L 40 ng/L NA
Manufacturer data, bibliography references [3—5].
CV: coefﬁcient of variation; LoB: Limit of Blank; LoD: Limit of Detection; LoQ: Limit of Quantitation; NA: not available.
a The smallest concentration of troponin obtained with reliable precision, i.e. with a 10% CV (see ‘What does analytical precision mean?’).
b Point-of-care biochemistry analyser.
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The gain in analytical sensitivity from conventional to
high-sensitivity assays has translated into a change in unit,
where high-sensitivity assay results are expressed in ng/L
instead of g/L [5]— a change that simpliﬁes the reporting
of results statements.
In practice/takeaways
• An assay qualiﬁes as’ high-sensitivity if it
demonstrates≤ 10% total imprecision at the 99th
percentile of a reference population and is able to
quantitate at least 50% of healthy individuals.
• cTn assays —whether high-sensitivity or
conventional— are not standardized.
• Not all cTn assays share the same level of precision
at low cTn concentrations.
• Each cTn assay has its own characteristics and cut-
off thresholds, which makes it vital to always use the
same assay to monitor the same patient.
• The results of hs-cTn assays are expressed in ng/L.
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ohat is an MI?
eﬁning an MI has always been tricky. The problem is that
ou have to identify a clinical-anatomical process based
n a combination of indirect criteria, as ‘hard’ anato-
opathological ﬁndings are rarely used in human subjects.
or the academic societies, this means that deﬁning an
I involves determining relevant ‘proxy’ criteria and their
pper-bound/lower-bound thresholds.
hy does the universal deﬁnition of an MI
ombine diagnostic criteria with a series of
nfarction types?
ince the early 1960s, there have been regular efforts to
stablish these criteria, to realign them as the technologies
merge and improve, and to establish some kind of consen-
us. Up until WHO-MONICA, which served as the benchmark
ntil the late 1990s, an MI was deﬁned based on an electro-
ardiogram (ECG) and pathological Q-waves. The validation
f troponins as a reliable speciﬁc biomarker of myocardial
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njury led ﬁrst the biochemistry societies then the cardiol-
gy societies to refocus the deﬁnition onto biomarkers, with
roponins leading the way. The European Society of Cardiol-
gy (ESC)/American College of Cardiology redeﬁnition of an
I in 2000 marked this turning point.
Initial fuzziness in the redeﬁnition, together with swift
nd steady progress in the assay techniques, prompted a
etweaked ‘redeﬁnition’ of MI a few years later. In 2007,
he biochemistry and cardiology societies joined forces to
ropose what was dubbed a ‘universal deﬁnition’ of an MI,
here ‘universal’ means that the deﬁnition pools all clin-
cal settings qualiﬁed as an MI; this has gained very broad
onsensus. The universal deﬁnition gave an even more cen-
ral role to cTn. The third version —a second update— of
he universal deﬁnition was published in 2012 [6].
This fairly radical deﬁnition of an MI has had two major
onsequences: a strong jump in the incidence of clinical
ettings qualiﬁed as infarction [7]; and, perhaps of even
ore concern, mounting confusion over where to draw the
ine between the concept of an MI and other clinical settings
ssociated with myocardial injury. This second concern only
merged with the improvement in assay procedures. Back in
000, when MI was ‘redeﬁned’, the performance quality of
Tn assays put them on a par with creatine kinase assays, and
nly enabled them to pick up the high concentrations typical
f relatively large MIs and certain forms of myocarditis.
To get a sharper picture of MI in light of its redeﬁnition,
t was necessary to look beyond the ﬁrst strand of baseline
iochemical, clinical, ECG and imaging characteristics used
o deﬁne an MI. The deﬁnition thus integrated a second ‘clin-
cal classiﬁcation’ strand, split into ﬁve types (numbered 1
o 5).
The deﬁnition is only universal if it is taken as a whole -
.e. the criteria plus the clinical types. This makes it crude
nd, in fact, ultimately wrong to simply say that an individ-
al has had an ‘infarction’ - you need to say that they have
ad a ‘type-n infarction’, as it is the type that effectively
ndicates the immediate severity for triage and treatment
trategy.
In practice/takeaways
• Deﬁnitions of MI are based on combinations of
consensus-based indirect criteria.
• Increase in cTn concentration was ﬁrst put forward as
a pivotal criterion in 2000 and has since taken centre
stage.
• The improvement in cTn assays achieved by
reducing cTn speciﬁcity for infarction compelled the
deﬁnition to introduce the concept of subcategories
or ‘types’ of infarction on top of the consensus-built
clinical criteria for deﬁning myocardial necrosis.
hich criteria were ﬁnally selected for
dentifying an MI?
he universal deﬁnition of an MI works up from the general
eﬁnition of myocardial injury with cell necrosis: ‘cardiac
iomarker values (preferentially troponin) with at least one
t
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alue above the 99th percentile of the upper reference limit
URL)’.
For this myocardial necrosis to qualify as an infarction, it
as to be associated with at least two other conditions. First,
compulsory condition of haemodynamic kinetic evidence
hat the myocardial injury occurred in a clinical setting
f acute myocardial ischaemia: ‘detection of rise and/or
all’. Second, there must be at least one further criterion
esigned to help conﬁrm that the clinical setting is consis-
ent with recent myocardial ischaemia: clinical symptoms
f ischaemia; development of pathological Q-waves in the
CG; new or presumed-new signiﬁcant ST-segment changes
r new left bundle branch block (LBBB); imaging evidence of
ew loss of viable myocardium or new regional wall motion
bnormality; identiﬁcation of an intracoronary thrombus by
ngiography (or autopsy).
Note that neither the scale of the rise (or fall) nor its
pper-bound/lower-bound cut-offs are detailed.
In practice/takeaways
• The deﬁnition of infarction is centred on the concept
of myocardial necrosis/injury, which is itself deﬁned
by a cTn assay value above the 99th percentile of a
reference population.
• To strengthen the probability that this damage is
ischaemic, the deﬁnition speciﬁes that myocardial
injury has to been combined with conditions based
on cTn kinetics (rise and/or fall) plus either clinical,
ECG or imaging criteria.
ow are the different infarction types
eﬁned?
his ﬁrst strand of the deﬁnition is already a source of confu-
ion, as it refers back to a broad and diverse range of clinical
nfarction settings. To address the issue, the deﬁnition goes
n to propose ﬁve types of MI: two - types 1 and 2 - are
linical; three - types 3, 4 and 5 - are wholly arbitrary.
linical deﬁnitions: types 1 and 2
ype 1 is deﬁned as spontaneous (sometimes dubbed ‘wild’)
I related to ischaemia caused by a primary coronary event,
uch as atheromatous plaque erosion and/or rupture, ﬁssur-
ng or dissection, along with fresh intracoronary thrombus.
Type 2 is deﬁned as instances of myocardial injury with
ell necrosis where a condition other than plaque rupture
ontributes to an imbalance between myocardial oxygen
upply and/or demand, e.g. anaemia, respiratory failures,
rrhythmias, hypotension or hypertension with or without
eft ventricular hypertrophy. By extension, coronary artery
pasm and coronary embolism not tied to plaque rupture are
lassiﬁed under type 2.
It is abundantly clear that the deﬁnitions of type 1 and
ype 2 have nothing to do with ST-segment elevation or non-
T-segment elevation. ST-segment elevation MI (STEMI) is
ractically always type 1. NSTEMI will split into either type
or type 2 depending on clinical features.
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Arbitrary deﬁnitions: types 3 to 5
These deﬁnitions cover settings where the clinical picture
points strongly to infarction, but the classical criteria are
missing (type 3), and settings where infarction is clearly
identiﬁed, but applying the classical criteria strictly is
irrelevant (types 4a and 5).
Type 3 is deﬁned as sudden unexpected cardiac death
with symptoms suggestive of myocardial ischaemia, accom-
panied by presumably new ST-segment changes or new LBBB,
occurring before biomarkers were obtained or before car-
diac biomarker values would be increased.
Type 4a is deﬁned as MI related to percutaneous coro-
nary intervention, arbitrarily deﬁned by an elevation of cTn
values over 5-fold the 99th percentile URL, and symptoms
suggestive of myocardial ischaemia and/or new ischaemic
ECG changes or new LBBB and/or angiographical or imaging-
demonstrated criteria.
Type 4b is deﬁned as MI associated with stent thrombosis,
as documented by coronary angiography or at autopsy in the
setting of myocardial ischaemia. The threshold used is the
99th percentile URL, associated with a rise and/or fall of
cardiac biomarker values.
Type 5 is deﬁned as MI associated with coronary artery
bypass graft, arbitrarily deﬁned by an elevation of cTn
values over 10-fold the 99th percentile URL in a patient
with normal baseline values, plus symptoms suggestive of
myocardial ischaemia and/or new ischaemic ECG changes or
new LBBB and/or angiographical or imaging-demonstrated
criteria.
The text accompanying the third version of this universal
deﬁnition spends more time justifying the selected criteria
than clarifying them [6].
In practice/takeaways
• The ﬁrst strand of the deﬁnition is already a source
of confusion, as it refers back to a broad and diverse
range of clinical infarction settings.
• The second strand of the deﬁnition speciﬁes the
criteria for ﬁve types of MI, with widely different
mechanisms, prognoses and treatment options.
• It is the type of infarction that indicates its
immediate severity for triage and treatment
strategy; MI type must always be stated.
• The two types that are most relevant to clinical
practice are type 1 (caused by plaque rupture)
and type 2 (caused by an imbalance between
myocardial oxygen supply and demand); only type
1 MIs are covered under strategies and treatments
recommended in the guidelines.
hs-cTn and MI
How are hs-cTn cut-offs determined and what
does the 99th percentile of a normal
reference population mean in practice?The cut-off is the value at the 99th percentile of a refer-
ence population. This reference population should ideally
be representative of the general population.
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The 99th percentile value of a cardiac biomarker is the
ut-off value below, which 99% of values obtained in the
ormal reference population fall.
The cut-off is tough to establish, as there is no estab-
ished consensus on the characteristics of a ‘normal’
opulation. The demographics of the subjects enrolled in
he reference population should be known, and investiga-
ions should be completed to conﬁrm the absence of heart
isease. Tougher selection criteria tend to result in lower
9th percentile values. The sample has to be large enough,
nd — ideally— the reference population should be charac-
erized in terms of cardiological health [8,9].
For the so-called conventional cTn assays, if imprecision
t the 99th percentile is too high (CV > 10%), the lowest
oncentration with a CV of 10% should be used as the cut-off
1]. For hs-cTn procedures, the cut-off is the 99th percentile
s, by deﬁnition, the CV at this level is≤ 10% [6].
In practice, the 99th percentile URL with its 95%
onﬁdence interval is determined from a homogeneous pop-
lation, following approved guideline procedure, using a
on-parametric test [10]. As the proportion of subjects with
etectable troponin levels increases, the 99th percentile
alculated gains in precision. It takes at least 300 subjects
ith detectable troponin levels to calculate a 99th per-
entile to a probability of 95% [11]. European academic
ociety taskforces have singled out this point as one of
he critical issues surrounding hs-cTn assays [5]. Age, sex
nd renal function can all inﬂuence the 99th percentile
9,12,13].
It is recommended that the assay reference values of the
edical laboratory population are veriﬁed (and readapted
f appropriate). International medical laboratory accredita-
ion standard ISO 15189 stipulates that the veriﬁcation of
iological analysis reference intervals should be based on
t least 100 healthy subjects (which, in this context, means
ree of chest pain and MI) [14].
In practice/takeaways
• The cut-off value for hs-cTn assays is the 99th
percentile.
• The 99th percentile value of a cardiac biomarker is
the cut-off value below which 99% of values obtained
in the population under study fall.
• The 99th percentile value can vary for a given assay
and a given target reference population according to
a series of factors that need to be identiﬁed.
• Standard ISO 15189 stipulates that the veriﬁcation of
biological analysis reference intervals is to be based
on at least 100 healthy subjects.
hat is the analytical precision reached at
his cut-off?
he cut-off used to diagnose MI has to be clearly speciﬁed.
ccording to the ESC 2012 consensus document, optimal
nalytical precision at the 99th percentile should be deﬁned
s a CV≤ 10% [6].
The manufacturer-stated CV can be biologically veriﬁed
y a precision proﬁle—20 measurements made on at least
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wo different reagent batches and with two different cal-
brators, over a window of > 20 days. Manufacturer data do
ot always add up to literature ﬁndings [5]; for this reason,
ocal medical biologists are advised to run tests to double
heck the manufacturer-claimed assay precision (see ‘What
recautions does the laboratory need to take when transi-
ioning to a hs-cTn assay?’).
Analytical precision can also be gauged via intermediate
recision (intralaboratory reproducibility), which again, in
his context, should be regularly veriﬁed, particularly for
alues close to the decision cut-off. Given the potential for
nterreagent-batch variation, this information needs to be
e-evaluated as and when successive batches get used.
Assay accuracy and imprecision need to be cross-veriﬁed
gainst the value obtained with an independent quality
ontrol test. Biologists should always opt for the cTn concen-
ration that gets closest to the decision limit cut-off.
In practice/takeaways
• The analytical CV at the 99th percentile must
be≤ 10% for hs-cTn assays.
• The 10%CV can be veriﬁed by a precision proﬁle.
re there other decision cut-offs?
n certain speciﬁc populations, a decision cut-off for rul-
ng in a diagnosis of MI can be calculated via a receiver
perator curve (ROC) [15], which helps to determine an opti-
al hs-cTn concentration in terms of clinical speciﬁcity and
ensitivity. Reiter et al. found that the optimal hs-cTnT cut-
ff decision limit for elderly subjects (aged > 70 years) was
4 ng/L, which is about 4-fold the 99th percentile URL of
younger reference population [16]. Some teams advocate
sing the 75th percentile of a normal population as a means
f increasing the negative predictive value of the cTn assay
or diagnostic rule out of MI [17].
In practice/takeaways
• A decision limit cut-off optimized for
speciﬁcity/sensitivity or designed to ﬁnd the
optimal speciﬁcity can be established using a ROC
curve in a given population group.
hat kind of improvements are hs-cTn assays
xpected to bring to patients with chest pain?
espite demonstrating outstanding cardiac speciﬁcity, the
ajor criticism levelled at conventional troponin assays was
heir inability to deliver an early diagnosis of acute MI (AMI),
hich is why other earlier markers (myoglobin, copeptin)
ere endorsed. Furthermore, the majority of conventional
ssays were unable to meet the analytical target precision
f < 10% at the academic society taskforce-recommended
eference cut-off (99th percentile). High-sensitivity assays
ere therefore developed with a two-fold objective: earlier
etection of troponin release after an ischaemic episode;
t
c
gC. Chenevier-Gobeaux et al.
nd improved precision and analytical sensitivity of the deci-
ion limit cut-off [18].
Most of today’s high-sensitivity assays now meet the ana-
ytical objective and can factor in any elevation approaching
his cut-off with < 10% precision at the 99th percentile deci-
ion cut-off with reliably high conﬁdence. Note too that
nalytical sensitivity has now reached a point where low-
evel troponin release can be picked up straight from early
tage myocardial cell necrosis or from the minute there is
ny change in cardiomyocyte membrane permeability [19].
Consequently, even a slight rise of fall in cTn can now be
etected very early on, from the very start of clinical signs
uggestive of acute coronary syndrome (ACS). This means
hat diagnostic sensitivity is increased from the minute
atients get to emergency medical services. Early studies by
eller et al. [20] and Reichlin et al. [21], which have since
een conﬁrmed in several more recent studies, showed that
sing hs-cTn (I or T) in combination with a 99th percentile
ecision cut-off can improve MI detection from as early as
hours after chest pain starts (increase in area under the
OC curve from 0.7 to > 0.9). Note, however, that at this
ime, the diagnostic value of hs-cTn has only been validated
n chest pain settings.
Nevertheless, low troponin concentrations in many clin-
cal settings involving non-ischaemic aetiology still end up
ecreasing marker speciﬁcity for MI diagnosis. This means
hat to improve diagnostic speciﬁcity, repeat assay and anal-
sis of dynamic cTn kinetics remain essential back-ups to
linical features and ECG ﬁndings. Given how early cTn ele-
ation can be picked up with high-sensitivity assays, in 2012
he cardiology society taskforce proposed new algorithms to
rack and trend cTn kinetics ‘live’ (see ‘What kind of time
nterval has to be left between two hs-cTn assays?’) [6].
In practice/takeaways
• High-sensitivity assays make it possible to:
◦ reach high precision (10%CV) at the 99th
percentile decision cut-off,
◦ rapidly detect troponin very early on,
◦ improve the diagnostic performances of cTn for
ACS screening;
• The increased sensitivity comes at the cost of
decreased speciﬁcity for a single cTn measure.
hy is it necessary to run a second assay,
ven with hs-cTn?
he deﬁnition of an MI hinges on detecting a rise and/or
all of circulating cTn values and so requires at least
wo measurements, performed on at least two blood sam-
les— ideally one drawn at admission and another drawn
—6hours post-admission [6] (see ‘Which criteria were
nally selected for identifying an MI?’).
Repeat hs-cTn assays prove doubly valuable because they
an rule out an MI with maximal safety and certainty, and
hey can rule in a diagnosis of type 1 MI with adequate
ertainty.
Patients with suspected MI swiftly get triaged to emer-
ency medical wards, with most getting management in the
tly a
l
l
t
t
T
h
w
b
c
[
1
h
t
h
i
t
W
s
T
c
v
c
i
t
s
[
v
v
g
c
s
g
(
w
o
a
(
c
i
i
hHigh-sensitivity cardiac troponin assays: Answers to frequen
ﬁrst 2 hours after onset of symptoms. Even with the high-
sensitivity assays, these short time windows do not always
leave enough time to demonstrate elevated cTn. Conse-
quently, a sub-cut-off troponin value at admission is not
enough to safely rule out an MI diagnosis, so a second repeat
assay at 3 hours post-admission proves necessary.
ESC guidelines on the management of non-ST-segment
elevation ACS do, however, authorize a single assay in cases
where patients report at least 6 hours of evolving chest
pain [22]; in which case, if hs-cTn stays below the cut-off
and there is no other aetiology warranting hospitalization,
patients can then be sent back home provided they no longer
present chest pain, but do present a GRACE score < 140. Note
that is there is a heavily suspected diagnosis, and if the sec-
ond repeat assay turns up a sub-cut-off value, it may be
advisable to run a third cTn assay to safely and reliably rule
out MI.
If cTn is elevated to above the cut-off at the ﬁrst cTn
assay AND there is a heavily suspected diagnosis, the rec-
ommendations on non-ST-segment elevation ACS leave it
open to the clinician whether or not to run the second
assay [22]. A recent opinion paper recommended per-
forming the second repeat hs-cTn assay regardless of the
value of the ﬁrst cTn assay [5]. The rationale is that
the increased sensitivity of cTn assays has come at the
cost of decreased speciﬁcity, and there are several sett-
ings that can still drive the hs-cTn value up and over the
decision cut-off (see ‘In what kind of setting can hs-cTn
increase, outside of type 1 MI?’ and ‘Does the level of
hs-cTn elevation point to aetiology?’): root causes of type
2 MI, such as anaemia, tachyarrhythmia/bradyarrhythmia,
hypotension/hypertension, hypoxia [6]; multifactorial or
indeterminate causes (acute neurological injury, heart fail-
ure, catecholamine-induced cardiomyopathy and others)
[6]; chronic causes, for which the cut-off limit in new-
generation hs-cTn assays is above the URL of a ‘healthy
adult’ reference population, such as advanced age, heart
failure, prior history of coronary heart disease or renal fail-
ure [6,13,23].
In these settings, assay-to-assay variation in cTn value
will not be signiﬁcant and, associated with evaluation of
clinical features, cannot be used as grounds for diagnosing a
deﬁnitive type 1 MI and, consequently, setting up an invasive
strategy.
In practice/takeaways
• It is recommended to run a second cTn assay to rule
in or rule out a diagnosis of non-STEMI in patients
presenting early within the ﬁrst hours of onset of
chest pain symptoms.
What kind of time interval has to be left
between two hs-cTn assays?
ESC guidelines from 2012 on the deﬁnition of MI advocate
repeating a second cTn assay 3—6hours later if using a con-
ventional cTn assay and at 3 hours if working with hs-cTn
[6]. ESC guidelines from 2011 on the management of non-
ST-segment elevation ACS advocate a second assay 3 hours
T
C
T
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ater, and even a third assay 6 hours later if there is a strong
ikelihood of MI [22]. It is equally possible to work to the
emplate given by Thygesen et al. in a review paper on how
o use hs-cTn measurements (Fig. 2, borrowed from [5]).
his algorithm is essentially built from research work with
s-cTnT. Consequently, other high-sensitivity assay methods
ill need to be validated in prospective clinical trials to
enchmark their performances and verify the diagnostic efﬁ-
iency of the patterns of cTn change recommended in 2012
6].
A study recently tested the beneﬁts of a second assay at
hour post-admission, using hs-cTnT at different hour 0 to
our 1 changes and baseline cut-offs, depending on whether
he aim was to rule out or rule in MI. The study yielded
ighly promising results, but without further conﬁrmation,
t cannot be taken as grounds for recommending a shorter
ime interval to the second assay [24].
In practice/takeaways
• A 3-hour interval between two serially tested cTn
samples is sufﬁcient when using an hs-assay in the
setting of chest pain with suspected ACS.
• New algorithms with shorter time intervals have
been proposed, but they need to be corroborated
by further studies.
hen does a change in hs-cTn become
igniﬁcant?
he total variation in medical test results stems from a
ombination of two types of variation: individual subject
ariation (biological variation, annotated CVi); and analyti-
al variation (CVa). The limit variation between two results
n a healthy and/or stable subject can now be evaluated
hrough the so-called reference change value (RCV).
RCV = 2½ × Z× (CVa2 + CVi2)½, where Z is a probability
core (Z = 1.96 for signiﬁcance with 95% conﬁdence level)
25]. This calculation is considered negligible for analytical
ariation. The RCV is the acceptable limit of result-on-result
ariation in a normal clinically stable subject. Any variation
reater than the RCV can be considered clinically signiﬁcant.
With the ﬁrst-generation conventional assays, cTn
oncentration was only quantiﬁable in a minority of healthy
ubjects, and so biological variation was considered negli-
ible because the baseline cTn value was non-quantiﬁable
i.e. it did not differ far enough from the LoD). However,
ith high-sensitivity assays, biological variation now takes
n signiﬁcance. Wu et al. studied short-term (within-day)
nd long-term (between-day) biological variation in hs-cTnI
Singulex® assay) in healthy subjects [26], and found that
TnI demonstrates low intraindividual variation, but high
nterindividual variation— in other words, cTnI shows high-
ndividuality. Troponin T responded the same way with the
s-cTnT assay [27]. The short-term RCVsmeasured by ARCHI-
ECT (Abbott), Vista (Siemens), Access 2 (Beckmann) and
entaur (Siemens) assays are around the 50% range [27].
he RCV of hs-cTnT varies in the 38—58% range, depending
n the study [27,28]. Note that the RCV calculation can be
140 C. Chenevier-Gobeaux et al.
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tigure 2. Algorithm for the diagnosis of acute coronary syndrome
ccording to [5].
pplied to relative change variations (in ng/L) or absolute
hange variations (in %) (see ‘Elevated hs-cTn values and
nfarct size’). Apple and Collinson [2] proposed a short recap
etailing the ﬁrst work on the RCVs of hs-cTn assays—work
hat started to shape the key concepts for interpreting time-
ourse patterns of hs-cTn with a variation-based template.
In practice/takeaways
• The RCV indicates the URL of acceptable variation
between two sample measurements in a healthy
subject; it varies with the hs-cTn assay used.
• The RCV applies to hs-cTn values≤ 99th percentile.
• The global RCV, all hs-cTn assays included, is
around the 50% mark; a relative variation > 50% of
concentrations observed at the 99th percentile is
to be considered clinically signiﬁcant; an absolute
change variation cut-off can prove an advantage in
terms of classifying patients.
• hs-cTn assays are high-individuality tests, for which
the notion of individual kinetics is more informative
than straight reference to ‘normal’ values.
s it best to use absolute change or relative
hange variation in hs-cTn? Does zero change
ule out a type 1 MI?he guidelines to using cTn advocate using the 99th per-
entile decision cut-off and the evaluated kinetics cTn
hanges (rising or falling variation) [6]. Level of change has
a
c
c
TcTn: high-sensitivity cardiac troponin; p.: percentile.
ot been evaluated with all the hs-cTn assays on the mar-
et. The change calculation can be expressed either as an
bsolute change value (cTn hour 3− cTn hour 0, expressed
n ng/L) or as a relative change value (%= [cTn hour 3− cTn
our 0]/cTn hour 0, expressed in %).
Opting to work with absolute change value variation
akes it possible to modulate the interpretation accord-
ng to initial hs-cTn concentration. The rationale is that in
bsolute values, the variation can often prove considerably
reater than the RCV (% of change tied to biological and
nalytical variability) if the initial hs-cTn concentration is
articularly low, yet well below the RCV if the initial hs-cTn
oncentration is already high (Fig. 3). It is always going to be
ifﬁcult to obviate≥ 50% increases in areas under the curve,
here initial concentrations are comfortably over the 99th
ercentile URL.
Reichlin et al. showed, using repeat cTn assays 2 hours
ost-admission, that the absolute changes were diag-
ostically superior to relative (percentage) changes with
he Roche hs-cTnT assay (absolute change decision cut-
ff = 7 ng/L) and the Siemens cTnI-ultra assay (absolute
hange decision cut-off = 20 ng/L) [29]. These ﬁndings have
ince been conﬁrmed by Mueller et al. with the hs-cTnT
ssay and a 6-hour delay between the two samples (absolute
hange decision cut-off = 7 ng/L) [30]. Similarly, Wildi et al.
howed that absolute changes were diagnostically superior
o relative changes with the Vista and Beckman hs-cTnI
ssays, especially in patients presenting early in response to
hest pain [31]. However, with other assays, relative change
an prove efﬁcient. Keller et al. showed with the ARCHI-
ECT hs-cTnI assay that a 30% relative change associated
High-sensitivity cardiac troponin assays: Answers to frequently a
Figure 3. Graphical representation of relative and absolute
changes, calculated with two values (V1 and V2). There is no
equivalence between the two calculations in the lowest values
(absolute change > relative change) or in the highest values (relative
change > absolute change).
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cally perfect speciﬁcity (98%) despite verymodest sensitivity
(56%) for the diagnosis of ACS [32].
For hs-cTn assays, a low ﬁrst-line troponin value < 99th
percentile and a relative change < RCV can rule out acute
cardiac injury. Nevertheless, the evidence suggests that cli-
nicians are more comfortable working in terms of absolute
change. A study recently showed that an hs-cTnT assay
repeated at 3 or 6 hours performs equally efﬁciently for
rule in or rule out of non-STEMI (absolute change decision
cut-off = 7 ng/L at 3 hours and 9 ng/L at 6 hours) [33].
Clearly then, the diagnostic performance and calculation
of cTn change (% and absolute ﬁgures) will need to be
estimated separately for each hs-cTn assay. Furthermore,
as there are still no standardized protocols, clinical valida-
tion studies need to be carried out to optimize timing of
the change interval and interpretation of the change pat-
terns.
There is a whole series of conditions where heart dam-
age translates into a cTn value above the 99th percentile
cut-off value. This situation, already well described with
conventional troponins [34], has become even more common
with the advent of hs-cTn assays because of their zoom-
in effect on the lower values and their gain in precision.
The differentiation between an acute change (tending to
suggest an acute coronary episode) and a chronic eleva-
tion (tending to suggest chronic myocardial injury) has not
been deﬁnitively validated. It is important to note that tro-
ponin change proﬁles similar to those seen in MI can also
be found in other different disease settings, as reported
by Wu [35], which makes it vital to interpret any dynamic
change in cTn value in relation to clinical presentation
(Fig. 4).
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In practice/takeaways
• The signiﬁcance of change between two cTn
measurements is assay dependent.
• The cTn change-range cut-offs published in academic
society guidelines are grounded in scattered
literature data.
• The change-from-baseline cut-offs need to be
validated for each high-sensitivity assay.
levated hs-cTn values and infarct size
everal studies have demonstrated that hs-cTnT concen-
rations are directly related to infarct size and extent of
oronary lesions, whether in STEMI patients [36] or NSTEMI
atients [37]. The same team found a similar relationship
ith hs-cTnI, where the correlation was signiﬁcant (r = 0.67;
< 0.001) [38]. Twenty-four-hours hs-cTnT was signiﬁcantly
orrelated to myocardial necrosis size, as obviated by 48-
our cumulative creatine kinase release (r = 0.86; P < 0.001)
36].
Although hs-cTn assays detect cTn release earlier than
heir older conventional cTn assays, time-to-peak blood lev-
ls (around 18—24 hours) and fall pattern are still the same.
In practice/takeaways
• hs-cTn values are correlated to infarct size.
• cTn fall kinetics follow the same pattern in a high-
sensitivity assay as in its older original conventional
protocol.
s-cTn elevation outside of type 1 MI
hat does an elevation in hs-cTn signify in
erms of pathophysiology?
he cardiomyocyte has two troponin pools. The ﬁrst is a
ytosolic pool composed of free troponin I (minority compo-
ent) and troponin T (majority component, accounting for
round 8% of the total troponin). The second pool, composed
f the three troponin subunits (I, T and C) is integral to the
uscle contraction complex (the actin-myosin-troponin pro-
ein complex). To recap, myocardial tissue only contains the
Tn isoforms I and T.
In myocardial ischaemia, the free cytosolic troponin may
e ﬁrst to be released. If the ischaemia is intense and/or
rolonged, the cell starts to necrotize, all free troponin
ets released, the contractile system collapses and/or is
estroyed and the complexed troponin is then second to get
eleased.
On top of the many forms of troponin (binary and ternary
omplexes) already found in circulating blood, the action
f various proteases can add further heterogeneity [39]. In
ractice, only the free or complexed cTn isoforms I and T
re effectively quantiﬁable.
142 C. Chenevier-Gobeaux et al.
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tigure 4. Classiﬁcation of abnormally high cardiac troponin (cT
ccident; LVH: left ventricular hypertrophy; p.: percentile; PCI: pe
Conventional cTn assays were only able to quantify the
trong elevations that signalled cardiomyocyte necrosis, giv-
ng no indication as to the type (see MI classiﬁcation scheme)
nvolved. The advent of high-sensitivity assays made it pos-
ible to quantify the release of strictly cytoplasmic troponin
6] (see ‘Can hs-cTn elevation reﬂect myocardial distress
ithout necrosis?’).
Although the theory posits that that only cTn isoforms
re measured and that there is no interference from muscle
soforms, the real story can turn out to be a lot more com-
licated. Indeed, a study just published has reported the
nthinkable: the in-muscle re-expression, against a back-
round of congenital myopathy, of an atypical isoform of
roponin T interfering with the hs-cTnT assay [40]. This does,
owever, remain an exceptional condition—and one that is
asily clinically identiﬁable.
In practice/takeaways
• The cardiomyocyte has two troponin pools: a
cytosolic pool and a pool integral to the muscle
contraction complex.
• There is strong heterogeneity in the blood-
circulating cTn forms.
i
o
cncentrations. CAD: coronary artery disease; CVA: cerebrovascular
neous coronary intervention; URL: upper reference limit.
an hs-cTn elevation reﬂect myocardial
istress without necrosis?
igh-sensitivity methods now open the way to detect-
ng not just strong elevations, but also low releases of
potentially cytoplasmic) troponin occurring in tandem with
yocardial distress without necrosis. As things stand, the
revailing opinion is that increases in cTn reﬂect necro-
is of cardiomyocytes. The hypothesis of troponin release
ithout myocardial necrosis in myocardial ischaemia has
een suggested in experimental trials [41] in patients
ith chronic exertional angina stabilized under treat-
ent, but also in healthy subjects [42]. Once again,
he pain could be tied to coronary heart disease, non-
oronary heart disease or non-heart disease. In all these
ettings, the elevated cTn is associated with poor progno-
is.
Among non-coronary diagnoses, the latest ESC guidelines
ist renal failure, heart failure, extreme tachyarrhyth-
ias/bradyarrhythmias, pulmonary embolism andmyocardi-
is as frequently responsible for elevated hs-cTn [6].
Rounding up, recent studies have reported a possible rise
n cTn in settings other than suspected MI—patients at risk
f atherosclerosis are an example. Here again, the rise in
Tn carries a bleak prognosis, and the post-admission care
High-sensitivity cardiac troponin assays: Answers to frequently a
Table 2 The four families of ‘acute’ increases in blood
cardiac troponin concentrations.
Type 1 myocardial ischaemia
Plaque rupture
Intraluminal coronary artery thrombus formation
Type 2 myocardial ischaemia related to oxygen
supply/demand imbalance
Tachyarrhythmias/bradyarrhythmias
Cardiogenic, hypovolemic or septic shock
Acute respiratory failure
Severe anaemia
Severe hypertension with or without LVH
Hypertrophic cardiomyopathy
Aortic dissection or decompensated severe aortic valve
disease (AI, AR)
Injury not related to myocardial ischaemia
Cardiac contusion, ablation, pacing or deﬁbrillator
shock
Cardiotoxic agents (e.g. Herceptin®, anthracycline
antibiotics)
Myocarditis
Rhabdomyolysis with cardiac involvement
Multifactorial or indeterminate myocardial injury
Heart failure
Stress (takotsubo) cardiomyopathy
Severe pulmonary embolism
Sepsis and any distress syndrome justifying intensive
care
Renal insufﬁciency
Severe acute neurological disease (e.g. stroke,
subarachnoid haemorrhage)
Inﬁltrative disease (e.g. amyloidosis)
Strenuous exercise
AI: aortic insufﬁciency; AR: aortic regurgitation; LVH: left
ventricular hypertrophy.
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◦ Non-ischaemic increases in cTn,period comes with an increased risk of mortality, not just
because of AMI, but also heart failure [43].
In practice/takeaways
• An elevation in hs-cTn may point to cardiomyocyte
disease or necrosis.
• This elevation carries a bleak prognosis.
• It opens up another potential ﬁeld of
application—prognostic stratiﬁcation in at risk
populations.
In what kind of setting can hs-cTn increase,
outside of type 1 MI?Outside of type 1 MI, elevated cTn concentrations can be
grouped into four broad settings (Fig. 4, Table 2).sked questions 143
etting 1
ype 2 MI relates to an imbalance between myocardial
xygen supply and/or demand (a ‘mismatch’) at a given
oint in time. This mismatch can prove relatively modest
f the cardiac muscle has already been damaged by chronic
athology (ischaemic, diabetic, hypertensive, valvular or
ther cardiomyopathy). The main causes are clinical sett-
ngs involving severe anaemia, hypotension or hypertension,
ypoxia, irregular heartbeat (fast or very slow) or a sud-
en sharp increase in myocardial oxygen demand— factors
hat will generally be associated (e.g. in extreme physi-
al exertion, sepsis, pulmonary oedema or shock). Clearly,
hen, most cases of increasing cTn in the wake of noncardiac
urgery will fall into the category of type 2 MI. The universal
eﬁnition of MI clearly indicates that a mismatch type 2 MI
s possible even with normal coronary arteries.
etting 2
he second setting is myocardial necrosis in which myocar-
ial ischaemia has been deﬁnitively ruled out. In this setting,
he term infarction gives way to ‘myocardial damage’.
he setting spans cardiac trauma, myocardial inﬂammation
myocarditis) and chemotherapy-induced cardiotoxicity.
etting 3
third setting covers multifactorial or indeterminate clin-
cal settings, as myocardial ischaemia has the potential to
lay a role in necrosis indirectly (Table 2). The boundary line
ith MI type 2 is often hazy [6].
etting 4
he fourth and ﬁnal setting involves stable baseline con-
entrations and abnormal troponin elevation. These cases
nvolve few patients at general population scale (0.04% of
eople in the 30—65 years age bracket according to the
allas Heart Study [44,45]), but a far higher proportion in
atients presenting at emergency medical services. This is
rare yet challenging population with numerous risk fac-
ors. The prevalence of circulating forms, which is very
ow with conventional cTn assays [45], increases sharply
nce hs-cTn assays are used [44]. There is a typically high
revalence of left ventricular hypertrophy, diabetes and
oronary calcium scan score > 100. Increased baseline cTn
n certain chronic clinical conditions, chieﬂy renal failure
nd heart failure, reﬂect the severity of the cardiomy-
pathy or the fragility of the underlying cardiovascular
tructure. In these patients, elevated cTn is a biomarker
f very high risk of medium-term cardiovascular accident or
ortality.
In practice/takeaways
• Elevated hs-cTn concentration can be grouped into
ﬁve broad diagnostic settings:
◦ Type 1 MI,
◦ Type 2 MI,◦ Multifactorial or indeterminate clinical settings,
◦ Chronic stabilized rise in cTn.
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oes level of hs-cTn elevation point to
etiology?
here are several classic clinical settings associated with an
ncrease in hs-cTn. In contrast to conventional cTn assays,
hich can be interpreted semi-quantitatively, hs-cTn assays
ave to be interpreted fully quantitatively, as cTn concen-
ration and measure-to-measure change can differ with
ifferent aetiologies.
An international team reported hs-cTnT concentrations
nd patterns of change in repeat assays in 887 patients
mean age 64 years) presenting with chest pain [46]. Patients
ith type 1 AMI had higher biomarker concentrations on
dmission: median hs-cTnT was 113 ng/L vs. 12 ng/L in
atients with cardiac non-coronary chest pain and 7 ng/L in
atients with noncardiac chest pain. Furthermore, hs-cTnT
oncentration increased in type 1 AMI patients at repeat
ssay compared with in other-cause patients: increase in
s-cTnT from ﬁrst to second assay was 19 ng/L within 1 hour
nd 63 ng/L within 6 hours in AMI patients versus 1 ng/L at a
-hour interval and 2 ng/L at a 6-hour interval in patients
ith cardiac non-coronary chest pain. Finally, analysis of
iomarker concentrations stratiﬁed for aetiology showed
hat only myocarditis presented a similar hs-cTn proﬁle to
he pattern found in AMI (strong elevation at admission rising
ven higher at repeat assays).
The scale of the increase in hs-cTn in patients presenting
ith chest pain can guide diagnosis towards different dis-
ase settings, which we can schematize as shown below.
ery high hs-cTn concentrations
n the vast majority of cases (> 90%), these will point to
MI (without stratifying between type 1 or type 2). The
ain differential diagnoses are myocarditis and takotsubo
ardiomyopathy. Repeat assay could further reﬁne the diag-
osis: further elevation from ﬁrst to second measure points
o a type 1 MI (or myocarditis).
ow hs-cTn concentrations on admission
ith further elevation from ﬁrst to second measure
his pattern points to the same proﬁle as very high hs-cTn
oncentrations on admission followed by further elevation
rom ﬁrst to second repeat.
table from ﬁrst to second measure
his setting points to a cardiac non-coronary cause. The
articular case of only slight low elevations showing no
igniﬁcant variation over time is often associated with non-
ecompensated heart failure.In practice/takeaways
• Blood-circulating cTn concentrations and change
from ﬁrst to second measure differ with different
aetiologies; analysis of these two variables is
critical to diagnostic thinking in any chest pain
patient.
i
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• The highest concentrations and measure-on-
measure increases are observed in type 1 MI;
against this background, the main differential
diagnoses are myocarditis and takotsubo
cardiomyopathy.
• Low change in hs-cTn at admission with no signiﬁcant
further increase from ﬁrst to second measure points
ﬁrst-line treatment towards a cardiac non-coronary
cause.
edical biology practice
re there hs-cTn assay protocol-related
alse-positives or false-negatives?
igh-sensitivity assay-related analytical false-positive or
alse-negative elevations of cTn do potentially exist, but
here have been few attempts to describe and study them
t this time. Every analytical factor takes on a critical
imension when dealing with hs-cTn. The fact is that
s-cTn assays are immunoassays, which means that
hey may well be exposed to the same analytical
nterferences as described previously for the older
onventional assays [3]. Consequently, the effects of
icroclotting, heterophilic antibodies or autoantibod-
es will all need to be estimated separately for each
s-cTn assay. To recap, the heterophilic antibodies
ncompass rheumatoid factor, natural and non-speciﬁc
nti-idiotypic antibodies, and human antianimal antibod-
es (including heterophilic human antimouse antibodies
HAMAs]).
In the high-sensitivity protocol development pro-
ess, some manufacturers reported modiﬁcations able
o decrease assay responsiveness against HAMAs when
sing chimeric antibodies in their immunoassay [47].
urthermore, analytical limits have already been
escribed—chieﬂy haemolysis interference potentially
nducing over- or under-estimation, depending on the assay
48]. Visually examining the specimen tube can provide an
valuation of sample quality, especially for samples drawn
hrough the intravenous catheter lines used in intensive
are units.
The assay result thus needs to be interpreted, not
ust in relation to clinical presentation and ECG pat-
erns, but also in relation to the analytical ‘environment’
presence of haemolyzed samples for instance), especially
hen none of the cardiac and noncardiac causes of ele-
ated cTn can be ruled in. Only HAMAs are easy to
creen for, using speciﬁc patent protected commercially
vailable tubes. Interferences from heterophilic antibod-
es can have varying degrees of impact depending on the
ssay protocol used, on much the same scale as in other
mmunoassays.
Note too that reports have shown that antitroponin anti-
odies can generate false-positives with conventional assays
49], and high-sensitivity assays may be exposed to this same
cenario.
High-sensitivity cardiac troponin assays: Answers to frequently a
In practice/takeaways
• Analytical false-positives (heterophilic antibodies
and haemolysis) have been reported for certain high-
sensitivity assays.
• Analytical false-negatives (essentially haemolysis)
have been reported for hs-cTnT.
• hs-cTn assays may well be exposed to the same
analytical interferences as described previously for
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What precautions does the laboratory need to
take when transitioning to a hs-cTn assay?
Any change in assay method is going to prove tricky. To main-
tain ﬁrm control over the transition process, it is crucial
that physicians/clinicians work hand-in-hand with medical
biologists.
In the laboratory
The assay needs to be veriﬁed in accordance with good
laboratory practice and in line with international medical
laboratory accreditation standard ISO 15189 [14]. First and
foremost, the analytical criteria on which the deﬁnition of
high-sensitivity assay is based (99th percentile, % measur-
able concentrations in patients) will need to be veriﬁed,
along with repeatability, intermediate precision, accuracy
and LoD and LoQ (both of which can be veriﬁed using a
precision proﬁle with cross-veriﬁcation of the 10%CV). Ide-
ally, veriﬁcation of the ‘normal’ values (determination of
the 99th percentile URL, % of detectable subjects) is also a
requisite.
In clinical services
In clinical services, particularly emergency services and
the cardiology ward, a review of the literature and deci-
sion algorithm scenario can be integrated alongside a more
practice-oriented biomarker evidence-based approach, such
as a comparative assay analysis. This process could include
cross-veriﬁcation against the literature-validated cTn rise
patterns and cut-off limits. To evaluate cTn change from
ﬁrst to second measure, in the absence of relevant litera-
ture data, analysts can fall back on a 50% RCV (see ‘When
does a change in hs-cTn become signiﬁcant?’). This strat-
egy is needed to enable clinicians to get a better grasp of
the analytical characteristics of the biomarker in their day-
to-day practice, as the transition to a hs-cTn assay is liable
to shake up their clinical practice routines as it entails a
repeat assay at a shorter (3-hour) interval and a jump in the
frequency of non-ACS cTn elevation syndromes [3,6].
Troponin taskforce
Signiﬁcant change patterns and cut-off values for ACS have
not been sharply detailed for a number of high-sensitivity
assays. This gap prompted the SFBC to coordinate the
creation of a taskforce pairing up medical biologists with
clinicians. The mission given to this national taskforce on
the ‘Use and interpretation of results with the latest hs-
cTn assays in Emergency Cardiology’ will be to compare the
s
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erformances of the troponin assays on the European market
nd, for each assay, to validate the recommended cut-offs,
he interval to re-analysis and the value signalling signiﬁcant
hange ( or %). The deliverables assigned to the task-
orce will be: to validate manufacturer-claimed diagnostic
fﬁciency of each assay; to propose individualized recom-
endations for the use of each assay; and to enable optimal
se of appropriate cTn assays in routine clinical practice.
In practice/takeaways
• The hs-cTn assay needs to be veriﬁed in accordance
with good laboratory practice and in line with
medical laboratory accreditation standards.
• Decision algorithm scenarios can be used alongside
a more practice-oriented biomarker evidence-based
approach via a comparative assay analysis.
• Signiﬁcant change patterns and cut-off values for
ACS have not been precisely detailed for a number
of high-sensitivity assays.
• To evaluate cTn change from ﬁrst to second measure,
in the absence of relevant literature data, analysts
can fall back on a 50% RCV.
ave any hs-cTn assays been validated for
oint-of-care biochemistry testing? Is
rehospital hs-cTn screening reliable?
he use of cTn assays outside the laboratory (point-of-care
esting) comes with a host of challenges, and so needs
o be tightly framed under a three-way contract between
he medical biologist, the clinician and the administra-
ive authority. This requires healthcare staff and ambulance
rews to be trained up on the technical procedures involved,
nd —of course— is governed by good laboratory practice
uidelines (referenced to accreditation standard ISO 22870).
Furthermore, the medical biologist retains sole respon-
ibility for the entire end-to-end analytical protocol— the
linician interpreting the result at the patient’s bedside
ust not lose sight of the fact that this ‘technical’ result
annot be deemed valid without medical biologist approval.
As of 2013, there is no validated hs-cTn assay available for
rehospital point-of-care in France: the only point-of-care
nd triage assays on the market lack sensitivity, which means
negative test result is not necessarily negative—largely
egating much of the beneﬁt brought by the faster diag-
ostic speed of the assay (Roche Cardiac Reader h232,
nverness Triage Meter, Samsung Labgeo IB10). That said,
high-sensitivity’ assays have found their way on board a
elect few point-of-care testers— the Siemens Stratus and
he Mitsubishi PATHFAST (Table 1). However, there are watch
oints.
The results of point-of-care testing or screening are nei-
her transposable nor comparable to results produced in
entralized labs, whichmeans the result of a prehospital test
esult must never be employed as an elevation test 0-hour
tart time if the subsequent assay measures are performed
ith other reagents back at the hospital.
Point-of-care assays are generally run on whole blood,
hich means the test will not pick up any sample haemolysis
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r dilution effects if the result is very high. Furthermore, the
etection and measurement ranges are narrow compared
ith assays done on central laboratory-based analysers [50].
In practice/takeaways
• There is no hs-cTn assay available for point-of-care
testing or screening.
• The results of point-of-care testing or screening
are neither transposable nor comparable to results
produced in centralized laboratories, which means
they must be interpreted strictly within the bounds
of the point-of-care tester.
• The use of cTn assays outside the laboratory
(point-of-care testing) needs a tight control
frame, procedural training for healthcare staff
and ambulance crews, and compliance with good
laboratory practice (international accreditation
standard ISO 22870).
rognostic value and therapeutic
trategies directed by hs-cTn
o all hs-cTn elevation levels in type 1 MI
ave the same prognostic value?
roponin concentration is tightly correlated to left ventricu-
ar function. In type 1 NSTEMI, it has long been recognized
hat cTn is a powerful short-term indicator of mortality or
arge MI. Very low cTn concentrations below the 99th per-
entile URL have a similarly strong prognostic value.
In practice/takeaways
• cTn concentrations are tightly correlated to risk of
fatality in type 1 STEMI and NSTEMI.
s hs-cTn elevation a prognostic marker
utside of type 1 MI?
n other clinical settings (type 2, non-ischaemic, multifacto-
ial, chronic), cTn elevations reﬂect the severity of cardiac
tress and/or cardiac muscle fragility.
For type 2 MI and myocardial lesions qualiﬁed as multi-
actorial or indeterminate, the increased risk of mortality
r cardiovascular accident with proportionally higher cTn
levation is stronger in the mid- to long-term than in the
hort-term. This is because, in these settings, the increase
n cTn concentrations indicates the intensity of cardiac
tress as a factor driving necrosis, but more important to
he bigger picture, the vulnerability of the cardiac mus-
le, regardless of its underlying cause (coronary disease,
ardiopathy, impaired coronary microcirculation, etc.). The
ame thinking applies to elevated baseline cTn above the
9th percentile URL in the general population in patients
resenting cardiopathy or clinical factors (renal failure,
a
e
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rterial disease, etc.) that point to increased risk of car-
iovascular accident. For the general population, mortality
nd cardiovascular event-free survival curves for individuals
ith chronic troponin elevation start to slide right from the
rst few weeks and continue to diverge over several years.
his risk is more than doubled at 3 years. This divergence in
urvival curves is even sharper when there is a background
f chronic disease, such as renal failure or heart failure.
Elevated cTn in non-ischaemic disease settings (pul-
onary embolism, cardiac trauma, aortic dissection,
yocarditis, anthracycline cardiotoxicity, sepsis, etc.) is
lso a risk marker, at least of extended hospital stay and
ften of mid-term cardiovascular events. In these patients,
Tn concentrations can be used for risk stratiﬁcation and
hoice of monitoring regimen, but with little inﬂuence on
reatment. However, at this time, there is still no consensus
n monitoring regimen for these patients, which (a priori) do
ot need to be triaged to the cardiac intensive care unit, and
till no clinical studies or ﬁrm recommendations on optimal
anagement strategy—whether to discharge early or admit
o hospital, which department to admit to and with what
bjectives.
In practice/takeaways
• Outside of type 1 MI, elevated cTn concentrations are
a marker of sufﬁciently intense systemic or cardiac
stress to cause myocardial lesions or of particularly
labile and structurally vulnerable cardiac muscle.
• Consequently, these cTn elevations are a powerful
predictive marker of mortality or mid-to-long-term
risk of cardiovascular accident.
• However, in a clinical context of non-ischaemic
increases in cTn, elevated cTn alone is not
sufﬁcient to determine/direct/decide any speciﬁc
management strategy.
iagnostic thinking and management policy
or chest pain patients
here we are sure
hen type 1 ACS is highly likely (based on clinical chest
ain data and cardiovascular risk factors, ECG readings
nd troponin elevation), an empirical treatment follow-
ng the latest 2011 and 2012 ESC guidelines should be
tarted (aspirin, antiplatelet, anticoagulant), regardless of
Tn concentration [6,22].
ontinued uncertainty
here is still no perfect clinical scoring scheme (even count-
ng the recently proposed Thrombolysis in MI [TIMI] score)
ble to state with certainty whether a troponin elevation
tems from developing infarction or from a non-coronary
r noncardiac cause. There is also no study demonstrating
hat starting a speciﬁc therapy (such as the one described
bove) for non-ST-segment elevation ACS is an absolute
mergency, and that holding back for minutes or even
ours will reduce the patient’s chances. Finally, there is no
tudy demonstrating that starting a speciﬁc therapy (aspirin
tly a
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and/or antiplatelet and/or anticoagulant) in response to a
non-coronary cause of elevated troponin is in any way use-
ful— indeed, there is a belief that it will expose patients to
undue risks of haemorrhagic complications.
In practice
The logical path forward, then, would be to propose a prag-
matic evidence-based approach to patient management in
response to elevated cTn.
If the clinical probability of type 1 non-ST-segment
elevation ACS is high, it would be logical to initiate a
guideline-recommended treatment [6] and —obviously after
conferring with the cardiologist— to transfer the patient to
the appropriate cardiac intensive care facility.
Conversely, if the clinical probability of type 1 ACS is low,
and especially if the second-reading cTn elevation is < 50% of
the ﬁrst reading and there is no change in ECG patterns, then
there is no logical rationale for proposing a treatment that
carries risks of haemorrhagic complications.
Finally, when faced with the middle road, where pre-test
likelihood is fair, but not high, and/or second-reading cTn
elevation is above the selected cut-off (see ‘When does a
change in hs-cTn become signiﬁcant?’ and ‘Is it best to use
absolute change or relative change variation in hs-cTn? Does
zero change rule out a type 1 MI?’), it would be logical to
initiate a treatment given the go-ahead by the cardiologist
and/or if there are changing ECG patterns and/or the patient
starts to present chest pain.
In practice/takeaways
• When there is strong suspicion of ST-segment
elevation ACS, an hs-cTn assay is redundant.
• In the other clinical settings, regardless of hs-
cTn start value or pattern of change, the values
cannot be interpreted without integrating clinical
probability (even if still estimated poorly by present-
day scoring schemes).
• It can only be integrated in a clinical diagnosis
and therapeutic strategy management algorithm for
routine use by interventionists after a three-way
discussion with cardiologists and biochemists.
The taskforce proposals for better routine
use of cTn
Coordinated by three French societies — the SFMU for emer-
gency medicine, the SFC for cardiology and the SFBC for
clinical biology —a taskforce was formed in late 2012 to
lead a multidisciplinary investigation on how to use cTn.
The taskforce has proposed a two-strand analysis: a review
of the literature and the state-of-the-art working practice
using cTn, reported here in question and answer format; and
hands-on comparative performance testing of hs-cTn assays.
The primary objective of this multidisciplinary approach is
to provide clinicians and biologists with answers to a series
of frequently asked questions on routine practice.sked questions 147
The second strand of this research documents the hour
to hour 3 cTn change patterns for each cTn assay tested,
n a multicentre non-selectively included cohort of patients
dmitted to an emergency room for chest pain with onset
ithin the previous 6 hours.
onclusions
iven the array of non-standardized assays on the market,
ffective use of hs-cTn hinges on knowing: the assay speciﬁc
haracteristics, particularly precision at the 99th percentile
eference population cut-off; the factors of variation at the
9th percentile; and the high-individuality of hs-cTn assays,
or which the notion of individual kinetics is more informa-
ive than straight reference to ‘normal’ values.
The published data, although dense, are still incomplete
t this time. The signiﬁcance of variation between two
ssays, which is method dependent, has not yet been docu-
ented for every hs-cTn assay. In this context, efforts should
e made to get clinicians working hand-in-hand with medical
iologists to extend the scope of knowledge for each assay
nd help to better understand how to use hs-cTn assays in
outine practice.
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